Core Scientific supplements proxy statement with director RSU values and DCF details to address merger lawsuits

Core Scientific, Inc./tx

Three stockholder lawsuits (CT and NY) and demands alleged proxy deficiencies; Core Scientific and CoreWeave deny merit but voluntarily supplement.
Supplemental disclosure: aggregate unvested RSU value for non-employee directors is $8,515,576, with individual amounts up to $1,972,906.
Moelis updated comparable company analysis tables; PJT Partners provided DCF discount rates and terminal value multiples for Core Scientific and CoreWeave.
No change to merger terms; supplemental disclosures intended to moot litigation without admission of liability.

item 8.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001140361-25-038945
form_type: 8-K
ticker: CORZ
cik: 0001839341
company_name: Core Scientific, Inc./tx
filed_at: 2025-10-22T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.742182+00:00
generated_at: 2026-05-17T02:48:30.761922+00:00
sec_items: ["8.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001140361-25-038945
json_url: https://secwatch.observer/filing/0001140361-25-038945.json
markdown_url: https://secwatch.observer/filing/0001140361-25-038945.md
text_url: https://secwatch.observer/filing/0001140361-25-038945.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1839341/000114036125038945/0001140361-25-038945-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1839341/000114036125038945/ef20057524_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001140361-25-038945

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.